Why the study?
Betatrophin is considered a therapeutic indicator of diabetes via insulin secretion, but the effects of different combined training intensities on irisin, betatrophin, and insulin required evaluation.
Does combined training at different intensities improve irisin, betatrophin, and insulin levels in women with type 2 diabetes?
Does combined training at different intensities improve irisin, betatrophin, and insulin levels in women with type 2 diabetes?
High-intensity combined training is more effective than moderate-intensity training at increasing irisin, betatrophin, and insulin levels in women with type 2 diabetes.
Should not yet change practice in women with T2D; leaves open whether intensity-related hormone changes improve glycemic or CV outcomes.
Background: Betatrophin is a β-cell proliferation marker produced as a result of irisin expression. It is regarded as a therapeutic indicator of diabetes due to elevated insulin secretion. Objectives: The purpose of this study was to compare the effects of 2 different intensities of combined training on the levels of irisin, betatrophin, and insulin in women with type 2 diabetes. Methods: In this study, 26 female patients with type 2 diabetes were divided into 3 groups of combined high-intensity training, combined moderate-intensity training, and control. The training groups participated in combined training at high or moderate intensities for 8 weeks. The variance analysis test and the Duncan post-hoc test were applied to analyze the data (P > 0.05). Results: Combined training at 2 intensities of moderate and vigorous led to a rise in the levels of irisin, betatrophin, and insulin. Exercise intensity was a determining factor for these elevated levels insofar as combined high-intensity training resulted in higher levels of these hormones than combined moderate-intensity training. Conclusions: It appears that participating in relatively high-intensity training programs may be beneficial for diabetic patients inasmuch as they increase the levels of irisin, betatrophin, and then, insulin.
No takes yet. Share an insight, caveat, or question.
Enteshary et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: